Melanoma Institute Australia welcomes new CEO Matthew Browne
9 August 2018
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
Matthew, who takes up the position effective immediately, brings to the organisation a wealth of experience in managing organisations involved in health care and major infrastructure projects.
He has been with Melanoma Institute Australia since January 2017, having performed the roles of Chief Financial Officer and Company Secretary, and more recently Acting CEO. Prior to joining Melanoma Institute Australia, Matthew was Acting CEO for Cure Brain Cancer Foundation and held a variety of senior executive roles responsible for Transport NSW’s Opal smartcard ticketing project, including Director of Ticketing.
Matthew holds a Bachelor of Economics from Macquarie University and has been a member of the Institute of Chartered Accountants in Australia since 1990.
Chairman of Melanoma Institute Australia, Mr Grant King said; “We are excited to welcome Matthew as CEO of Melanoma Institute Australia as his leadership skills and experience in the medical research and not for profit sectors will ensure the organisation continues to be a world leader in melanoma prevention, treatment and cure.”
“Given Matthew’s previous executive roles, including at Melanoma Institute Australia, we are confident his transition into the CEO role will be smooth and effective and the organisation will continue its momentum towards its mission of zero deaths from melanoma,” he said.
“I am delighted and honoured to be leading such a world-class organisation,” Matthew Browne said. “I am proud of the achievements made by Melanoma Institute Australia over many years, providing patients with melanoma the very best standard of care and more life-saving treatment options.
“Melanoma Institute Australia is deeply committed to achieving its mission, and it will truly be a time to celebrate when that day arrives,” he said.
For more information, please contact:
Jennifer Durante |Melanoma Institute Australia | 0412 798 990 | firstname.lastname@example.org
Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.
We have a winner!
Professor John Thompson, Executive Director at Melanoma Institute Australia, was one of 116 fellows appointed to the new Australian Academy of Health and Medical Sciences at a ceremony in Canberra on the 25th March.
Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.
If you would like to download a bib for your Melanoma March, we have a selection for you to choose from, print and bring along with you on the day.
Manly Melanoma March has changed to a new location.
We did a short Q&A with two sisters who are raising funds for Melanoma March after sadly losing their mother in 2009. This is their second march and they have shared with us their fundraising tips.
We want to share with you what your valuable Melanoma March donation and fundraising goes towards and our Research Director, Graham Mann explains the national research project the funds will be going towards.
Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE FM) clinical trial has recruited its first patient.
You are invited to provide comments for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC will consider the registration of the anti-PD1 drug, Keytruda (pembrolizumab) at the next meeting in March.
Melanoma patient Joel Allsop was congratulated today on completing his participation in the international surgical clinical trial, known as MSLT-II. He was the first person in the world to complete the 10 years of follow-up for this trial.
Melanoma Institute Australia (MIA) has officially launched the 2015 ‘Melanoma March’ initiative in Melbourne.
Help us march towards a cure for melanoma research. See where your local march is and how you can get involved.
Under the leadership of world-leading melanoma pathologist Prof Richard Scolyer and medical oncologist A/Prof Georgina Long, third year PhD student, Hojabr Kakavand, is at the forefront of melanoma research.
Melanoma Institute Australia has launched a new smartphone app called ClinTrial Refer Melanoma to help busy clinicians find clinical trials for their melanoma patients.
MIA's Associate Professor Georgina Long and stage 4 melanoma patient, Maria, were recently interviewed by ABC Weekend Breakfast about the latest in clincial trials and melanoma treatments.
Sunbed campaigner, Jay Allen, has been acknowledged on the honour roll of Australia’s most influential people in the non-profit sector.
Today we launch the website we’ve dreamed about!
Our new summer campaign has you and your mates' backs covered!